Welcome to our dedicated page for Protalix BioTherapeutics SEC filings (Ticker: PLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protalix BioTherapeutics, Inc. filings document a commercial-stage biopharmaceutical issuer with NYSE American-listed common stock and a business built around recombinant therapeutic proteins produced through ProCellEx®. The company’s Form 8-K reports cover operating results, financial condition, business and clinical updates, corporate presentations, stockholder communications and regulatory events involving Elfabrio®.
Protalix’s proxy materials describe board governance, executive compensation, equity awards and shareholder voting matters. Its regulatory disclosures also identify material event reporting around European regulatory actions for Elfabrio, collaboration-related communications with commercialization partners, and the capital-market status of its common stock.
Protalix BioTherapeutics, Inc. reported substantially stronger results for the quarter and six months ended June 30, 2026. Total revenue for the first half of 2026 was $53.6 million, up from $25.8 million in 2025, and net income turned to a $22.1 million profit from a $3.5 million loss. Second quarter 2026 revenue was $19.9 million versus $15.7 million a year earlier, with net income of $3.8 million versus $0.2 million.
Growth was driven by higher revenues from selling goods, primarily continued global penetration of Elfabrio, and a $25.0 million milestone payment from Chiesi related to EU dosage approval. Cash and cash equivalents plus short-term deposits totaled $40.7 million at June 30, 2026, and the company states it has no outstanding debt or warrants. Management reaffirmed its 2026 revenue expectations and highlighted progress in the PRX-115 Phase 2 RELEASE trial and preclinical programs focused on rare renal indications, while indicating that future license and R&D service revenues are expected to be minimal aside from potential regulatory milestones.
BlackRock, Inc. reported beneficial ownership of common stock of Protalix BioTherapeutics Inc.. BlackRock beneficially owns 4,046,650 shares of common stock, representing 5.02% of the class. It has sole voting power over 3,982,603 shares and sole dispositive power over 4,046,650 shares, with no shared voting or dispositive power.
The shares are held by certain reporting business units of BlackRock and its subsidiaries and affiliates. Various underlying persons have rights to dividends or sale proceeds, but no single person has an interest in more than five percent of Protalix BioTherapeutics’ outstanding common shares.
Protalix BioTherapeutics held its 2026 annual stockholder meeting, where investors approved all proposals presented. Stockholders elected eight directors, with Eliot Richard Forster, Ph.D. receiving 32,871,013 votes for and 2,379,140 withheld, alongside 10,705,177 broker non-votes.
Investors approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 28,368,614 votes for and 6,683,937 against. They also approved an amended and restated 2006 Stock Incentive Plan, increasing the shares available under the plan from 17,475,171 to 20,975,171.
Stockholders ratified the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 42,958,243 votes for, 2,001,734 against, and 995,352 abstentions.
Protalix BioTherapeutics, Inc. filed a current report stating that on May 21, 2026 it posted a new corporate presentation on its website. The presentation is furnished as Exhibit 99.1 and, under the cited Exchange Act instructions, is treated as furnished rather than filed for liability purposes.
Protalix BioTherapeutics reported a strong turnaround for the quarter ended March 31, 2026. Total revenue rose to $33.8M from $10.1M a year earlier, driven mainly by $26.3M of license and R&D revenue that included a $25.0M milestone from Chiesi following EU approval of the every‑four‑weeks Elfabrio dosing regimen.
The company generated net income of $18.3M, versus a net loss of $3.6M in the prior‑year quarter, with basic EPS improving to $0.23. Product sales were $7.4M, down from $10.0M, reflecting lower Elelyso volumes to Pfizer and Fiocruz, partly offset by growing Elfabrio sales to Chiesi.
Operating cash flow was $22.0M, boosting cash and cash equivalents to $41.0M and total cash plus short‑term deposits to $51.1M. Total assets reached $102.3M and stockholders’ equity $67.2M. Management believes current cash resources and deposits can fund operations for at least 12 months as R&D spending increases, including the RELEASE study and early‑stage pipeline work.
Protalix BioTherapeutics reported sharply improved first quarter 2026 results. Total revenue rose to $33.8M for the quarter ended March 31, 2026, up from $10.1M a year earlier, driven mainly by $26.3M of license and R&D service revenue, including a milestone tied to Elfabrio’s European progress.
The company generated net income of $18.3M versus a net loss of $3.6M in the prior-year period, with diluted EPS at $0.22. Cash and cash equivalents increased to $41.0M, supporting a debt-free balance sheet. Management reaffirmed its 2026 revenue outlook and highlighted ongoing enrollment in the PRX-115 Phase 2 RELEASE gout study and continued focus on rare renal disease programs.
Protalix BioTherapeutics, Inc. will hold its 2026 annual stockholder meeting on June 25, 2026 in Tel Aviv. Holders of the 80,571,642 shares of common stock outstanding as of April 30, 2026 may vote.
Stockholders are asked to elect eight directors for one-year terms, approve on a non-binding advisory basis the compensation of named executive officers, and approve an amended and restated 2006 Stock Incentive Plan that raises the share reserve from 17,475,171 to 20,975,171 shares. They will also vote on ratifying Kesselman & Kesselman as independent auditor for 2026 and any other proper business.
The proxy details board and committee composition, independence, ownership and extensive executive pay information. In 2025, CEO Dror Bashan received total compensation of $1.17 million, while all directors and executive officers collectively beneficially owned about 5,576,142 shares, or 6.7% of the common stock.
Protalix BioTherapeutics, Inc. senior vice president and CFO Gilad Mamlok reports his equity holdings in an amended Form 3. He holds 3,631 shares of common stock directly. He also holds stock options covering 597,990 shares of common stock at an exercise price of $1.45 per share, expiring on July 20, 2035. These options vest in 12 equal quarterly installments from the grant date and can vest faster if there is a corporate transaction or change in control under the company’s Amended and Restated 2006 Stock Incentive Plan.
Protalix BioTherapeutics schedules a disclosure that MAK Capital Fund LP, MAK Capital One L.L.C. and Michael A. Kaufman beneficially own 3,616,289 shares of Common Stock, equal to 4.5% of the class.
The filing states the ownership figure is as of 03/30/2026 and cites 80,421,181 shares outstanding as of November 1, 2025 per the issuer's Form 10-Q.